---
layout: full_article
title: "POTENSI FOTODINAMIK SEBAGAI MODALITAS TERAPI ALTERNATIF NON INVASIF PADA ORAL CANCER STADIUM DINI:"
author: "Timotius William Yusuf, Jason Chen, Vincentius Mario Yusuf"
categories: essential
canonical_url: https://jurnal.harianregional.com/essential/full-77763 
citation_abstract_html_url: "https://jurnal.harianregional.com/essential/id-77763"
citation_pdf_url: "https://jurnal.harianregional.com/essential/full-77763"  
comments: true
---

<p><span class="font4" style="font-weight:bold;">ARTIKEL TINJAUAN PUSTAKA</span></p>
<p><span class="font1">Essence of Scientific Medical Journal (2022), Volume 20, Number 43-54</span></p>
<div><img src="https://jurnal.harianregional.com/media/77763-1.jpg" alt="" style="width:53pt;height:25pt;">
</div><br clear="all">
<p><span class="font1">P-ISSN.1979-0147, E-ISSN. 2655-6472</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font2" style="font-weight:bold;text-decoration:underline;"><a name="bookmark1"></a>TINJAUAN PUSTAKA</span></h1>
<h1><a name="bookmark2"></a><span class="font2" style="font-weight:bold;"><a name="bookmark3"></a>POTENSI FOTODINAMIK SEBAGAI MODALITAS TERAPI ALTERNATIF NON INVASIF PADA </span><span class="font2" style="font-weight:bold;font-style:italic;">ORAL CANCER</span><span class="font2" style="font-weight:bold;"> STADIUM DINI: TINJAUAN EFIKASI DAN PROFIL KEAMANAN</span></h1>
<p><span class="font1" style="font-weight:bold;">Timotius William Yusuf</span><span class="font1"><sup>1</sup></span><span class="font1" style="font-weight:bold;">, Jason Chen</span><span class="font1"><sup>1</sup></span><span class="font1" style="font-weight:bold;">, Vincentius Mario Yusuf</span><span class="font1"><sup>2</sup></span></p>
<h2><a name="bookmark4"></a><span class="font1" style="font-weight:bold;"><a name="bookmark5"></a>ABSTRAK</span></h2>
<p><span class="font1" style="font-weight:bold;">Pendahuluan: </span><span class="font1">Oral cancer didefinisikan sebagai keganasan yang terjadi pada kavitas oral dan kini menempati 10 besar penyebab kanker tertinggi sedunia. Tingkat mortalitas oral cancer masih tinggi dengan five-year survival rate hanya mencapai 50-60%. Tatalaksana saat ini bersifat invasif, berisiko tinggi, dengan berbagai efek samping yang berpotensi tinggi mengurangi efektivitas terapi hingga quality of life pasien. Berdasarkan studi terdahulu, fotodinamik merupakan modalitas terapi alternatif oral cancer stadium dini yang menjanjikan karena bersifat selektif dan non invasif dengan efikasi serta outcome klinis yang baik. Tinjauan pustaka dibuat dengan kriteria PICO dari studi klinis yang memenuhi kriteria inklusi. Studi diekstraksi dari database “PubMed”, “ScienceDirect”, dan “SpringerLink” menggunakan metode pencarian “boolean operator”.</span></p>
<p><span class="font1" style="font-weight:bold;">Pembahasan: </span><span class="font1">Terdapat total 11 studi klinis yang memenuhi kriteria inklusi dan menyatakan terapi fotodinamik efektif dalam tatalaksana oral cancer stadium dini. Efikasi klinis dilihat dari tingkat complete response dan survival rate yang baik disertai tingkat rekurensi yang rendah. Mekanisme yang melatarbelakangi efikasi yakni eksitasi photosensitizer memicu produksi reactive oxygen species yang mengakibatkan destruksi sel kanker. Selain itu juga ditemukan paparan fotodinamik dapat menyebabkan shut-down pembuluh darah jaringan tumor dan aktivasi sistem imun. Efek samping yang paling umum ditemukan adalah nyeri, pembengkakan, dan fotosensitivitas. Secara garis besar, efek samping tidak bersifat fatal, dapat dikendalikan dan tidak menyebabkan dampak fungsional maupun estetik yang persisten.</span></p>
<p><span class="font1" style="font-weight:bold;">Simpulan: </span><span class="font1">Fotodinamik efektif sebagai modalitas terapi alternatif non invasif pada oral cancer stadium dini dengan efikasi klinis dan profil keamanan yang baik.</span></p>
<p><span class="font1" style="font-weight:bold;">Kata kunci: </span><span class="font1">Oral Cancer, Photosensitizer, Stadium dini, Terapi Fotodinamik.</span></p>
<h2><a name="bookmark6"></a><span class="font1" style="font-weight:bold;"><a name="bookmark7"></a>ABSTRACT</span></h2>
<p><span class="font1" style="font-weight:bold;">Introduction: </span><span class="font1">Oral cancer is defined as a type of malignancy that occurs in the oral cavity and occupies the top 10 leading causes of cancer worldwide. Oral cancer mortality rate is high with a five-year survival rate of only 50-60%. The current treatment is invasive, risky, with severe complications that can reduce therapy efficacy and patients’ quality of life. Based on previous studies, photodynamics is a promising alternative therapy for oral cancer because of its selective non-invasive traits and good clinical results. This literature review was done based on PICO and determined inclusion criterias. Studies were extracted from “PubMed”, “ScienceDirect”, and “SpringerLink” databases using “boolean operator” search method.</span></p>
<p><span class="font1" style="font-weight:bold;">Discussion: </span><span class="font1">There were a total of 11 clinical studies that met the inclusion criteria and stated that photodynamic therapy was effective in the treatment of oral cancer. Clinical efficacy is seen from high complete response rates and survival rates accompanied by low recurrence rates. The mechanism underlying its efficacy is photosensitizer excitation triggers the production of reactive oxygen species that lead to the destruction of cancer cells. It was also found that photodynamic exposure can cause shut- down of tumor tissue blood vessels and activation of immune system. The most common side effects are pain, swelling, and photosensitivity. In general, side effects found are not fatal, can be controlled and do not cause lasting functional or aesthetic impacts. Conclusion: Photodynamic is effective as a non-invasive therapy modality in oral cancer with good clinical efficacy and safety profile.</span></p>
<p><span class="font1" style="font-weight:bold;">Keywords: </span><span class="font1">Early Stage, Oral Cancer, Photosensitizer, Photodynamic therapy.</span></p>
<div>
<ul style="list-style:none;"><li>
<p><span class="font1"><sup>1</sup> &nbsp;&nbsp;&nbsp;Pendidikan Dokter Gigi, Fakultas Kedokteran Gigi, Universitas Trisakti, Jakarta Barat</span></p></li>
<li>
<p><span class="font1"><sup>2</sup> &nbsp;&nbsp;&nbsp;Pendidikan Dokter, Fakultas Kedokteran, Universitas Brawijaya, Malang</span></p></li></ul>
</div><br clear="all">
<h2><a name="bookmark8"></a><span class="font1" style="font-weight:bold;"><a name="bookmark9"></a>PENDAHULUAN</span></h2>
<p><span class="font1">Oral cancer didefinisikan sebagai neoplasma ganas yang muncul pada bibir atau rongga mulut. Penyakit ini secara tradisional didefinisikan sebagai OSCC (oral squamous cell carcinoma). Insiden oral cancer menempati peringkat sepuluh besar jumlah kanker terbanyak di dunia.[1] Berdasarkan WHO Cancer Register, diperkirakan terdapat 350 kasus baru dan 50 ribu kematian tercatat pada tahun 2017. Oral cancer merupakan penyakit serius dengan hanya setengah dari total pasien yang bertahan hidup dalam jangka lima tahun setelah diagnosis (50-60% five-year survival rate). [2] Hingga kini oral cancer menjadi salah satu penyakit keganasan yang sering terjadi di negara berkembang, salah satunya Indonesia. Berdasarkan data dari WHO, terdapat 5.780 kasus baru, 3.087 kematian dan 5 tahun prevalensi oral cancer sebanyak 14.197 kasus di Indonesia.[3]</span></p>
<p><span class="font1">Lebih dari 90% tumor ganas di daerah mulut adalah SCC (squamous cell carcinoma) yang berasal</span></p>
<p><span class="font1">dari epitel mukosa.[4] Etiologi terjadinya karsinogenesis SCC merupakan proses multifokal sangat kompleks yang terjadi ketika epitel squamosa dipengaruhi oleh berbagai perubahan genetik.[5] OSCC (oral squamous cell carcinoma) muncul dari lapisan epitel dari rongga mulut dengan fitur histopatologis khas berupa “conventional” squamous cell carcinoma. Kriteria untuk menentukan diagnosis karsinoma adalah adanya invasi sel epitel melalui membran basal ke jaringan ikat superfisial. Invasi dimulai melalui proses penyusupan (breaching) dari beberapa sel atau pulau epitel kecil, dan berprogesi menjadi infiltrasi pada submukosa ataupun tulang oleh lembaran dan pulau-pulau sel ganas. Proses invasi ini memunculkan tanda klinis klasik berupa indurasi yang terfiksasi pada jaringan di bawahnya. Lesi dengan ukuran lebih besar dapat berkembang melebihi suplai darahnya, sehingga menimbulkan tanda klinis ulserasi pada permukaan tumor. Pada pemeriksaan mikroskopis, semua squamous cell carcinoma memiliki komponen invasif, di mana pulau</span></p>
<p><span class="font1">tumor dapat diliat pada permukaan epitel bagian dalam.[4]</span></p>
<p><span class="font1">Pada oral cancer, merokok dan alkohol dianggap sebagai faktor risiko utama yang terdapat pada 90% kasus, melakukan keduanya dapat menimbulkan efek sinergis. [1] Konsumsi tembakau terus menjadi risiko kanker oral yang paling prominen karena diperkirakan menyebabkan jutaan kematian setiap tahunnya.[6] Alkohol (etanol) meningkatkan permeabilitas mukosa mulut, melarutkan komponen lipid/ lemak dari epitel, menyebabkan atrofi epitel dan gangguan pada sintesis dan perbaikan DNA; juga memiliki efek genotoksisitas dan mutagenik, penggunaan kronisnya dikaitkan dengan penurunan kekebalan bawaan dan adaptif, mengakibatkan peningkatan kerentanan terhadap infeksi dan neoplasma.[1]</span></p>
<p><span class="font1">Terdapat berbagai cara kuratif dalam penatalaksanaan oral cancer, umumnya dilakukan dengan tindakan pembedahan, kemoterapi, dan radioterapi yang dapat dilaksanakan secara individual maupun bersamaan.[7] Tindakan pembedahan menjadi penanganan utama terhadap penatalaksanaan oral cancer stadium dini seperti pengangkatan tumor primer, manajemen dari limfonodi servikal, dan lain-lain.[8] Meskipun tindakan pembedahan adalah penanganan yang ideal untuk oral cancer, lokasi lesi yang terdapat pada struktur-struktur organ kritis seperti arteri karotis, basis cranii, rongga orbital, dan rongga intrakranial menjadi limitasi tindakan operatif karena bersifat invasif dan berisiko tinggi. [9] Hal tersebut juga didukung dengan penurunan quality of life (QOL) pasien yang umumnya membutuhkan tindakan pembedahan rekonstruktif setelah pembedahan resektif pada tumor. Tindakan ini dilakukan akibat kehilangan gigi dan keberadaan luka pasca operasi yang menyebabkan kehilangan fungsi dan estetik dalam jaringan yang sehat.[7,11] Meskipun kemoterapi dan radioterapi merupakan pilihan kedua terbaik setelah tindakan pembedahan, efikasi dan pengaplikasian kemoterapi dan radioterapi terhadap pasien sering terganggu dikarenakan risiko kardiositotoksisitas, nefrotoksisitas, myelosupresi, neurotoksisitas, dan hepatotoksisitas yang mengurangi QOL dari pasien dan berpotensi mengakibatkan efek samping lain terhadap pasien kanker. [11]</span></p>
<p><span class="font1">Terapi fotodinamik telah muncul sebagai pilihan terapi alternatif atau lini kedua potensial terhadap oral cancer superfisial primer pada stadium dini dengan tingkat invasif yang minimal.[13] Rangkaian terapi fotodinamik meliputi injeksi dari obat photosensitizing (PS) sistemik yang diaktivasi dengan reaksi fotokimia melalui pemberian cahaya pada panjang gelombang tertentu pada situs tumor. Hal tersebut akan memicu produksi dari reactive oxygen species (ROS) dan mengakibatkan oksidasi molekular yang berakibat pada penghancuran dari neoplasma. Terapi ini dapat mendestruksi jaringan tertentu secara spesifik dengan interaksi antara oksigen, cahaya, dan PS sistemik. [12-14]</span></p>
<p><span class="font1">Ada beberapa kelebihan dari metode terapi fotodinamik, yakni: (1) Terapi fotodinamik tidak menyebabkan toksisitas sistemik; (2) Terapi dapat menghancurkan tumor secara selektif selagi mempertahankan keberadaan jaringan normal; (3)</span></p>
<p><span class="font1">Terapi ini dapat diulangi kembali di area anatomi yang sama tanpa komplikasi terhadap terapi selanjutnya; (4) Terapi fotodinamik meminimalisir pembentukan bekas luka hasil operasi lebih baik dibandingkan dengan tindakan pembedahan atau radioterapi sehingga meningkatkan QOL dari pasien; (5) Penanganan ini dapat dilakukan sebelum atau setelah &nbsp;&nbsp;dilakukannya &nbsp;&nbsp;penanganan &nbsp;&nbsp;secara</span></p>
<p><span class="font1">konvensional. [10] Namun disisi lain terapi fotodinamik dapat menimbulkan berbagai komplikasi seperti nyeri, fotosensitisasi residual, hingga edema/pembengkakan yang dapat menyebabkan dispnea dan disfagia pada pasien, sehingga terapi simtomatik, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adjuvan, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rehabilitatif</span></p>
<p><span class="font1">direkomendasikan selama pasien menjalani terapi.[7,10]</span></p>
<p><span class="font1">Berdasarkan temuan dan urgensi yang telah dipaparkan di atas, penulis memiliki sebuah inisiasi untuk melakukan tinjauan pustaka mengenai efektivitas fotodinamik sebagai modalitas terapi alternatif yang bersifat non invasif dengan efikasi klinis yang baik dalam terapi oral cancer.</span></p>
<p><span class="font1">Kajian pustaka dilakukan dengan pencarian jurnal sesuai kriteria inklusi melalui database PubMed, ScienceDirect, dan SpringerLink. Strategi pencarian artikel menggunakan boolean operator dengan kata kunci “Photodynamic therapy”, “Photodynamic chemotherapy”, “Oral cancer”, “Oral squamous cell carcinoma”, dan “Therapy”. Kriteria inklusi jurnal adalah 1) rentang tahun publikasi 20112021, 2) studi klinis orisinil berbahasa inggris, dan 3) memenuhi framework PICO (Tabel 1).</span></p>
<p><span class="font1" style="font-weight:bold;">Tabel 1</span><span class="font1">. Kriteria Inklusi Kajian Pustaka berdasarkan PICO </span><span class="font1" style="font-style:italic;">Framework</span></p>
<h2><a name="bookmark10"></a><span class="font1" style="font-weight:bold;"><a name="bookmark11"></a>Kriteria &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inklusi</span></h2>
<p><a href="#bookmark12"><span class="font1">I----------------------------------------------------11</span></a></p>
<p><span class="font1" style="font-style:italic;">Problems &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oral Cancer</span></p>
<p><a href="#bookmark13"><span class="font1">I----------------------------------------------------11</span></a></p>
<p><span class="font1" style="font-style:italic;">Intervention</span><span class="font1"> &nbsp;&nbsp;&nbsp;Penggunaan fotodinamik</span></p>
<p><span class="font1">sebagai modalitas terapi</span></p>
<p><a href="#bookmark14"><span class="font1">I----------------------------------------------------11</span></a></p>
<p><span class="font1" style="font-style:italic;">Comparation &nbsp;&nbsp;&nbsp;Outcome</span><span class="font1"> sebelum dan</span></p>
<p><span class="font1">sesudah intervensi atau fotodinamika dengan tindakan operatif</span></p>
<p><span class="font1">I----------------------------------------------------1------------------------------------------------------------------------------------------------1</span></p>
<p><span class="font1" style="font-style:italic;">Outcome</span><span class="font1"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Respons Terapi</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Tingkat rekurensi</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Survival rate</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Profil Keamanan</span></p></li></ul>
<p><span class="font1">Penelusuran dan evaluasi artikel berdasarkan kriteria inklusi dilakukan oleh ketiga penulis untuk menurunkan potensi bias akibat seleksi studi antar penulis. Berdasarkan hasil penelusuran artikel didapatkan 583 jurnal pada pencarian awal dan didapatkan 17 jurnal yang valid karena jurnal yang lainnya tidak memenuhi kriteria inklusi (n=566). Pada akhirnya, hasil analisis </span><span class="font1" style="font-style:italic;">full text</span><span class="font1"> didapatkan 11 jurnal akhir karena jurnal yang lainnya terduplikasi antar </span><span class="font1" style="font-style:italic;">database</span><span class="font1"> (n=6). Alur seleksi studi dirangkum dalam diagram alur pada Gambar 1. Karakteristik studi dilaporkan pada Lampiran 1.</span></p><img src="https://jurnal.harianregional.com/media/77763-2.jpg" alt="" style="width:184pt;height:151pt;">
<p><span class="font1" style="font-weight:bold;">Gambar 1. </span><span class="font1">Diagram Flow Alur Pencarian Artikel</span></p>
<h2><a name="bookmark15"></a><span class="font1" style="font-weight:bold;"><a name="bookmark16"></a>HASIL &amp;&nbsp;PEMBAHASAN</span></h2>
<h2><a name="bookmark17"></a><span class="font1" style="font-weight:bold;"><a name="bookmark18"></a>Efikasi Terapi Fotodinamik dalam Tatalaksana </span><span class="font1" style="font-weight:bold;font-style:italic;">Oral Cancer</span></h2>
<p><span class="font1">Sebelas studi </span><span class="font1" style="font-style:italic;">clinical trial</span><span class="font1"> yang memenuhi kriteria inklusi membahas potensi penggunaan fotodinamik sebagai terapi alternatif dalam penatalaksanaan </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> stadium dini. Semua studi klinis yang dikaji memaparkan adanya persetujuan dari komite kajian etik uji klinis setempat. </span><span class="font1" style="font-style:italic;">Sampling</span><span class="font1"> dari studi-studi yang dikaji dilakukan dengan menawarkan fotodinamik sebagai opsi alternatif pada pasien dengan </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> yang persisten dari terapi sebelumnya, rekuren, dianggap tidak </span><span class="font1" style="font-style:italic;">eligible</span><span class="font1"> ataupun menolak tindakan standar (</span><span class="font1" style="font-style:italic;">salvage surgery/reirradiation</span><span class="font1">). Pasien yang menyetujui dievaluasi eligiblitasnya oleh tim multidisipliner, pasien yang dianggap layak diberikan penjelasan </span><span class="font1" style="font-style:italic;">risk-benefit</span><span class="font1"> serta diminta </span><span class="font1" style="font-style:italic;">informed consent</span><span class="font1"> tertulis sebelum dilakukan intervensi. Secara umum, rangkuman hasil tinjauan digambarkan pada Tabel 2.</span></p>
<p><span class="font1">Dari hasil didapatkan fakta bahwa penggunaan terapi fotodinamik efektif dalam penatalaksanaan </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1">. Efektivitas yang dimaksud dilihat dari tingkat </span><span class="font1" style="font-style:italic;">complete response</span><span class="font1"> yang baik, tingkat rekurensi yang rendah, dan </span><span class="font1" style="font-style:italic;">survival rate</span><span class="font1"> yang baik dalam penatalaksanaan </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> dengan menggunakan terapi fotodinamik.</span></p>
<p><span class="font1">Beberapa studi melaporkan penanganan </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> stadium dini dengan terapi fotodinamik menggunakan PS mTHPC paling sering digunakan karena menghasilkan </span><span class="font1" style="font-style:italic;">outcome</span><span class="font1"> klinis yang relatif baik.<sup>[12-17]</sup> Hal ini dikarenakan PS mTHPC dapat mengeksitasi gelombang lebih panjang sehingga dapat mencapai penetrasi jaringan lebih baik dibandingkan dengan PS photofrin. Temuan ini didukung oleh studi oleh Jerjes di mana tingkat </span><span class="font1" style="font-style:italic;">complete response</span><span class="font1"> sebesar 81%, dengan tingkat rekurensi sebesar 11.6 %, dan 5-</span><span class="font1" style="font-style:italic;">year survival rate </span><span class="font1">sebesar 84.2 %.<sup>[16]</sup> Menurut RECIST, </span><span class="font1" style="font-style:italic;">complete response</span><span class="font1"> didefinisikan sebagai hilangnya semua lesi target setelah penanganan, sedangkan </span><span class="font1" style="font-style:italic;">partial response</span><span class="font1"> yaitu ketika terjadi setidaknya penurunan sekitar 30 persen jumlah diameter lesi target dibandingkan diameter awal. Berbeda dengan studi oleh Jerjes, studi oleh Karakullukcu yang</span></p>
<p><span class="font1">menggunakan mTHPC melaporkan hasil tingkat </span><span class="font1" style="font-style:italic;">complete response</span><span class="font1"> sebesar 45 %, </span><span class="font1" style="font-style:italic;">partial response </span><span class="font1">sebesar 40 % dan </span><span class="font1" style="font-style:italic;">no change</span><span class="font1"> sebesar 25 % dengan tingkat rekurensi 25 %.<sup>[14]</sup> Hal ini dikarenakan pada penatalaksanaan terapi, ada kemungkinan terjadinya “</span><span class="font1" style="font-style:italic;">geographical miss”</span><span class="font1"> atau dalam kata lain, sebuah area yang tidak menerima dosis cahaya yang cukup pada margin lesi yang diterapi tersebut.<sup>[14]</sup></span></p>
<p><span class="font1">Hasil studi Durbec tahun 2013 menunjukkan persentase </span><span class="font1" style="font-style:italic;">complete response</span><span class="font1"> sebesar 93.%, namun terdapat rekurensi sebesar 53.%.<sup>[18]</sup> Hal ini dapat terjadi dikarenakan beberapa faktor, pertama, anatomi rongga mulut sering mengalami keadaan abnormal berupa mulut tidak terbuka secara adekuat atau </span><span class="font1" style="font-style:italic;">mikrostomia</span><span class="font1"> sebagai akibat pengobatan sebelumnya. Hal ini dapat menghalangi paparan homogen menuju area tumor sehingga penyinaran tidak merata dan meningkatkan resiko terjadinya rekurensi. <sup>[18]</sup></span></p>
<p><span class="font1">Studi oleh Ikeda pada tahun 2018 melaporkan 25% pasien tetap menunjukkan </span><span class="font1" style="font-style:italic;">partial response </span><span class="font1">setelah diberi dua kali terapi fotodinamik dengan PS talaporfin sodium. Hal ini diperkirakan karena administrasi talaporfin sodium yang tidak adekuat ke dalam lesi tumor ganas. Sehingga menghasilkan hasil prognosis yang buruk. <sup>[7]</sup> Studi dari Ikeda pada tahun 2013 menunjukkan persentase rekurensi sebesar 12 %. Hal ini dikarenakan PS yang digunakan yakni photofrin memiliki panjang gelombang eksitasi sebesar 630 nm yang hanya dapat menembus jaringan hingga kedalaman 10 mm. Sehingga ditemukan adanya sisa tumor di dasar mulut pada satu pasien, bersamaan dengan rekurensi pasien lain pada langit-langit mulut atau mulut bagian palatal. Palatal dan dasar mulut memiliki struktur yang kompleks di dalam rongga mulut, dengan kedua tempat memiliki permukaan yang tidak teratur sehingga sulit untuk secara akurat menyinari struktur yang non-homogen. Oleh karena itu, kedalaman penetrasi yang tidak cukup dengan struktur yang kompleks mungkin menjadi faktor atas keberadaan sel tumor residual. <sup>[10]</sup></span></p>
<p><span class="font1">Dalam studi oleh Toratani dengan menggunakan PS photofrin, rekurensi pada lesi tumor merah lebih tinggi secara signifikan dibandingkan lesi putih (p=0.011).<sup>[19]</sup> Hal ini dipengaruhi faktor perbedaan warna pada lesi, di mana warna lesi bergantung pada derajat keratinisasi dan vaskularisasi, lesi putih memiliki tingkat keratinisasi yang tinggi sedangkan lesi merah mengandung banyaknya pembuluh darah. Hemoglobin pembuluh darah mengurangi absorbsi intensitas cahaya pada terapi PS photofrin, menyebabkan penetrasi lesi merah kurang efektif. Aktivasi photofrin yang lebih rendah pada lesi tumor merah menyebabkan respon klinis yang lebih buruk dibandingkan tumor lesi putih. Studi ini didukung dengan studi oleh Ikeda di mana keterbatasan kedalaman penetrasi merupakan salah satu kelemahan dalam penggunaan PS photofrin dan disarankan penggunaan PS generasi kedua seperti mTHPC dalam terapi fotodinamik</span><span class="font1" style="font-style:italic;">.</span><span class="font1"><sup>[19]</sup></span></p>
<div>
<p><span class="font1" style="font-weight:bold;">Tabel 2</span><span class="font1">. Tabel Rangkuman Efikasi Terapi Fotodinamik</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Penulis</span></p></td><td colspan="3" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;font-style:italic;">Response Rate</span><span class="font1" style="font-weight:bold;"> (%)</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;font-style:italic;">Recurrence</span><span class="font1" style="font-weight:bold;"> (%)</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;font-style:italic;">Survival Rate</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">CR</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">PR</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">NC</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Toratani et al., 2016<sup>[19]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">88.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">8.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2.9</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">26.5</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;5-year overall survival:</span><span class="font1"> 76.5%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-specific survival:</span><span class="font1"> 84.6%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-free survival:</span><span class="font1"> 63.3 %</span></p></li></ul></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">de Visscher et al.,</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Intervensi • TI: 86 •T2: 63</span></p></td><td style="vertical-align:top;"></td><td colspan="2" style="vertical-align:middle;">
<p><span class="font1">Intervensi • TI: 28.6 • T2: 53.3</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Overall Survival </span><span class="font1">Intervensi</span></p>
<p><span class="font1">• TI: 101.5 bulan • T2: 116.9 bulan</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">2013<sup>[15] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;r</sup></span></p></td><td style="vertical-align:top;">
<p><span class="font2">I</span></p>
<p><span class="font1">Kontrol:</span></p>
<p><span class="font1">• T1: 76</span></p>
<p><span class="font1">•T2:79</span></p></td><td style="vertical-align:top;">
<p><span class="font2">I</span></p></td><td colspan="2" style="vertical-align:middle;">
<p><span class="font1">Kontrol:</span></p>
<p><span class="font1">• T1: 29.3 • T2: 24.2</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-style:italic;">Overall Survival</span></p>
<p><span class="font1">Kontrol:</span></p>
<p><span class="font1">• T1: 122.6 bulan • T2: 109.5 bulan</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Ikeda et al., 2013<sup>[10]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">96</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">12</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">Disease-specific survival</span><span class="font1">: 95.8%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Ikeda et al., 2018<sup>[7]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">75</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">25</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">16.7</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Jerjes et al., 2011<sup>[16]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">81</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">8.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">10.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">11.6</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;3-year survival</span><span class="font1">: 92.1%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;5-year survival</span><span class="font1">: 84.2%</span></p></li></ul></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Jerjes et al., 2011<sup>[12]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">68.4</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">15.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">5 years survival</span><span class="font1">: 84.82%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Karakullukcu et al., </span><span class="font0"><sub>2011</sub>[13]</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">70.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">19.9</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">9.3</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">24.7</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;2-year local disease free</span><span class="font1">: 74%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;5-year local disease free</span><span class="font1">: 61%</span></p></li></ul></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Karakullukcu et al., 2012<sup>[14]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">45</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">40</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">15</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">25</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Karakullukcu et al., </span><span class="font0"><sub>2013</sub>[17]</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">89</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">11</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">-</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Local disease-free survival at 5 years</span><span class="font1">: 67%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-free survival at 5 years</span><span class="font1">: 47%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-free survival</span><span class="font1">: 63.3 %</span></p></li></ul></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Durbec et al., 2013<sup>[18]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">93.3</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">6.7</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">53.3</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Overall survival</span></p>
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">1 year:</span><span class="font1"> 72% • </span><span class="font1" style="font-style:italic;">3 year:</span><span class="font1"> 43% • </span><span class="font1" style="font-style:italic;">5 years:</span><span class="font1"> 36% </span><span class="font1" style="font-style:italic;">Disease-spesific survival</span></p>
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">1 year:</span><span class="font1"> 82% • </span><span class="font1" style="font-style:italic;">5 year:</span><span class="font1"> 45%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Rigual et al., 2013<sup>[20]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">88.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">8.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2.9</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">26.5</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;5-year overall survival:</span><span class="font1"> 76.5%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-free survival:</span><span class="font1"> 84.6%</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Disease-free survival rates:</span><span class="font1"> 63.3 %</span></p></li></ul></td></tr>
</table>
<p><span class="font1">CR, </span><span class="font1" style="font-style:italic;">Complete Response.</span><span class="font1"> NC, </span><span class="font1" style="font-style:italic;">No Change.</span><span class="font1"> PR, </span><span class="font1" style="font-style:italic;">Partial Response</span></p>
</div><br clear="all">
<h2><a name="bookmark19"></a><span class="font1" style="font-weight:bold;"><a name="bookmark20"></a>Mekanisme Terapi Fotodinamik</span></h2>
<p><span class="font1">Terapi fotodinamik merupakan terapi berbasis reaksi fotokimia yang bekerja dengan cara aktivasi komponen sensitif cahaya yaitu PS onkotropik untuk memicu kerusakan sel kanker secara selektif.<sup>[18] </sup>Dalam pelaksanaannya, PS diberikan secara topikal maupun intravena pada area tumor, PS kemudian terkonsentrasi pada sel-sel over-proliferatif dengan laju metabolisme tinggi dan defek struktur membran seperti sel kanker. <sup>[21]</sup></span></p>
<p><span class="font1">Foton dari laser dengan panjang gelombang yang berkorespondensi dengan daya absorbsi puncak spesifik PS diaplikasikan pada jaringan target untuk menghasilkan aksi sitotoksik bersama dengan oksigen.<sup>[10]</sup> Percepatan konsumsi molekul oksigen dapat dikendalikan melalui </span><span class="font1" style="font-style:italic;">power density</span><span class="font1">, semakin tinggi maka semakin besar pula penggunaan oksigen pada area terapi fotodinamik.<sup>[22]</sup> Proteksi jaringan sekitar yang sehat dapat dipastikan melalui </span><span class="font1" style="font-style:italic;">shielding </span><span class="font1">spons basah maupun </span><span class="font1" style="font-style:italic;">special shielding waxes</span><span class="font1">. <sup>[13]</sup></span></p>
<div><img src="https://jurnal.harianregional.com/media/77763-3.jpg" alt="" style="width:397pt;height:202pt;">
</div><br clear="all">
<p><span class="font1" style="font-weight:bold;">Gambar 2. </span><span class="font1">Rangkuman Mekanisme Kerja Terapi Fotodinamik terhadap Sel Kanker <sup>[23]</sup></span></p>
<p><span class="font1">Cara kerja terapi fotodinamik sebagai anti kanker dimulai dari PS yang tereksitasi secara langsung beraksi pada substrat (</span><span class="font1" style="font-style:italic;">unsaturated lipid, </span><span class="font1">protein, atau asam nukleat) untuk menghasilkan ROS seperti hidrogen peroksida (H</span><span class="font0">2</span><span class="font1">O</span><span class="font0">2</span><span class="font1">), radikal hidroksil (·OH), anion superoksida (O</span><span class="font0">2</span><span class="font5">•-) </span><span class="font1">melalui transfer proton maupun elektron (reaksi tipe 1).<sup>[24,25]</sup> Selain itu, PS tereksitasi dapat bereaksi dengan molekul oksigen melalui transfer energi untuk membentuk </span><span class="font1" style="font-style:italic;">singlet oxygen</span><span class="font1"> (<sup>1</sup>O2</span><span class="font1" style="font-style:italic;">)</span><span class="font1">, komponen sitotoksin mayor (reaksi tipe 2). <sup>[26]</sup> Radikal-radikal bebas ini menghasilkan efek tumorisidal direk, yang secara langsung mengganggu komponen seluler dari sel-sel kanker melalui oksidasi ireversibel dan memicu kematian sel melalui apoptosis jika PS terletak pada organel intraseluler (nukleus, mitokondria, lisosom, retikulum endoplasma) dan nekrosis jika PS terletak pada membran sel.<sup>[19,27]</sup></span></p>
<p><span class="font1">Selain itu, ditemukan terapi fotodinamik berakibat pada formasi nekrosom yang mengandung </span><span class="font1" style="font-style:italic;">receptor-interacting protein kinase 1</span><span class="font1"> (RIP1) dan RIP3 yang memicu nekroptosis. Mekanisme lainnya berupa aktivasi dari respons imun, fotosensitisasi memicu autofagosom yang juga mengakibatkan autolisosom untuk memecah komponen sitoplasma<sup>.[28]</sup> Rangkaian mekanisme dapat dilihat pada Gambar 2.<sup>[23]</sup> Selain autofagi, ROS yang diproduksi dari retikulum endoplasma juga memicu </span><span class="font1" style="font-style:italic;">damage-associated molecular models</span><span class="font1"> (DAMPS) yang pada akhirnya menstimulasi presentasi antigen dari sel dendritik dan proliferasi limfosit T sitotoksik (sel CD8<sup>+</sup>) dalam menarget sel kanker.<sup>[29]</sup> Telah diperkirakan juga terapi fotodinamik dapat mengakibatkan </span><span class="font1" style="font-style:italic;">shut-down</span><span class="font1"> pembuluh darah jaringan tumor melalui pembentukan trombosis dan konstriksi vaskular, yang mengakibatkan deprivasi oksigen serta nutrien sehingga menginduksi kematian sel kanker. <sup>[7]</sup></span></p>
<h2><a name="bookmark21"></a><span class="font1" style="font-weight:bold;"><a name="bookmark22"></a>Profil Keamanan Terapi Fotodinamik</span></h2>
<p><span class="font1">Sebagai metode pengobatan yang tergolong baru, keamanan adalah salah satu pertimbangan utama dari pasien. Efek samping dilaporkan pada total delapan studi dengan nyeri serta pembengkakan sebagai komplikasi yang paling umum ditemukan pada intervensi fotodinamik (Tabel 3). Adanya nyeri merupakan tanda adanya keberhasilan efek terapeutik yang ditemukan pada hari pertama maupun kedua dengan berbagai derajat keparahan dan bertahan selama 2-4 minggu. Nyeri berhasil ditangani dengan penggunaan analgesik seperti NSAID, dengan tambahan opioid oral, transdermal, dan enteral seperti morfin sulfat serta salep anestesi topikal, </span><span class="font1" style="font-style:italic;">patch</span><span class="font1"> transdermal fentanil dengan menyesuaikan kebutuhan pasien.<sup>[10,12,18-20]</sup> Studi oleh Jerjes et al., melaporkan nyeri diikuti peningkatan sementara dari konsentrasi sel darah putih, serta induksi nekrosis jaringan dan respons inflamasi akut hingga kronis.<sup>[16]</sup></span></p>
<p><span class="font1">Nekrosis muncul 2-3 hari setelah iluminasi dan bertahan sekitar 10-14 hari.<sup>[10,12]</sup> Luka nekrosis post iluminasi sembuh secara komplit tanpa pembentukan bekas luka ataupun dengan formasi bekas luka minimal pada tumor jaringan lunak setelah 4-6 minggu.<sup>[13,19]</sup> Hal ini dikarenakan komponen matriks jaringan seperti kolagen dan elastin dipertahankan, sementara elemen selular dan vaskular dirusak oleh terapi fotodinamik. Preservasi dari arsitektur jaringan dianggap menyediakan </span><span class="font1" style="font-style:italic;">scaffold</span><span class="font1"> yang baik untuk regenerasi jaringan normal dan menghasilkan pemulihan yang sangat baik tanpa bekas luka.<sup>[12,19] </sup>Selain itu, pembengkakan dan edema diobservasi 24 jam setelah iluminasi dan pulih setelah kurang lebih satu minggu.<sup>[10,12,20]</sup> Pembengkakan dan edema berisiko mengakibatkan obstruksi jalan napas dan dyspnea apabila lesi terletak pada basis lidah ataupun bagian posterior dari </span><span class="font1" style="font-style:italic;">oral floor</span><span class="font1">.<sup>[10]</sup></span></p>
<div>
<p><span class="font1">Untuk menangani </span><span class="font1" style="font-style:italic;">nasopharyngeal </span><span class="font1">memperlancar jalan</span></p>
</div><br clear="all">
<div>
<p><span class="font1">ini, &nbsp;&nbsp;&nbsp;dapat digunakan</span></p>
<p><span class="font1" style="font-style:italic;">tube</span><span class="font1">/</span><span class="font1" style="font-style:italic;">tracheotomy</span><span class="font1"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;untuk</span></p>
<p><span class="font1">napas. Sedangkan untuk</span></p>
</div><br clear="all">
<p><span class="font1">pemberian makanan dapat melalui </span><span class="font1" style="font-style:italic;">nasogastric feeding tube</span><span class="font1">/</span><span class="font1" style="font-style:italic;">enteral feeding liquid</span><span class="font1"> dan </span><span class="font1" style="font-style:italic;">pureed diet </span><span class="font1">hingga pasien pulih. <sup>[12-14,18.20]</sup></span></p>
<p><span class="font1" style="font-weight:bold;">Tabel 3</span><span class="font1">. Tabel Rangkuman Efek Samping Terapi Fotodinamik</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Efek Samping</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Referensi</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Jumlah (%)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">Ikeda et al., 2013<sup>[10]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 (8)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Jerjes et al., 2011<sup>[16]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Derajat ringan-sedang: 22(15)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Durbec et al., 2013<sup>[18]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Derajat 1: 2 (13.3)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Fotosensitivitas</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Jerjes et al., 2011<sup>[12]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Derajat 1: 2 (5.26)</span></p>
<p><span class="font1">Derajat 2: 3 (7.89)</span></p>
<p><span class="font1">Derajat 3: 1 (2.63)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Karakullukcu et al., 2011<sup>[13]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Derajat 2: 3 (1.76)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 (5.9)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">34 (100)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Ikeda et al., 2013<sup>[10]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">25(100)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Rigual et al., 2013<sup>[20]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">40 (100)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Nyeri &amp;&nbsp;Pembengkakan</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Jerjes et al., 2011<sup>[16]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Semua derajat: 147 (100) Derajat ringan-sedang: 126 (85.7)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Karakullukcu et al., 2012<sup>[14]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">20 (100)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">15(100)</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1">Disfagia sementara</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">1 (6.67)</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1">12 (7.05)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Diskolorasi Kulit</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">9 (5.29)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Formasi Sequestrum</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font1">4 (11.4)</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">Toratani et al., 2016<sup>[19]</sup></span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Perforasi Sinus Maxilaris</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">1 (2.9)</span></p></td></tr>
</table>
<p><span class="font1">Efek samping signifikan lainnya yakni reaksi fotosensitisasi residual sistemik, yang dapat bertahan beberapa hari hingga minggu bergantung pada PS yang diadministrasikan n.<sup>[12]</sup> Konsentrasi minor PS pada kulit dapat berakibat pada </span><span class="font1" style="font-style:italic;">sunburn,</span><span class="font1"> edema, hingga nekrosis superfisial ketika terekspos sinar atau cahaya intens. Maka dari itu, perlu dilakukan edukasi pasien terkait langkah-langkah proteksi dari eksposur cahaya.<sup>[7,10,16-18]</sup> Pada beberapa studi ditemukan pasien tidak patuh terhadap instruksi sehingga mengalami </span><span class="font1" style="font-style:italic;">skinburn</span><span class="font1"> derajat 1-3 namun pulih kembali dengan penanganan konservatif, terjadi pula edema fasial yang pulih dalam waktu 1 minggu setelah administrasi steroid.<sup>[13,18-20]</sup> Penggunaan PS photofrin berisiko mengakibatkan komplikasi</span></p>
<p><span class="font1">fotosensitisasi karena retensi yang berkepanjangan pada kulit. PS yang ideal dapat secara cepat tereliminasi dari jaringan normal sementara dipertahankan dalam jaringan neoplastik secara selektif.<sup>[19]</sup> PS generasi kedua seperti c</span><span class="font1" style="font-style:italic;">hlorophyll analogs</span><span class="font1">, talaporfin sodium, HPPH, dan temoporfin ditemukan dapat tereliminasi lebih cepat dibandingkan photofrin sehingga meminimalisir komplikasi fotosensitivitas.<sup>[7,18-20]</sup> Alternatif lainnya adalah 5-aminolevulinic acid (5-ALA), satu-satunya PS yang dapat diaplikasikan secara topikal sehingga pasien tidak harus menghindari eksposur cahaya setelah intervensi, namun efikasi terbatas pada kedalaman tumor 1-2 mm.<sup>[12]</sup></span></p>
<p><span class="font1">Hasil pemeriksaan laboratorium ditemukan normal, tidak ditemukan perdarahan mayor dan tidak ada </span><span class="font1" style="font-style:italic;">organ-related adverse reaction</span><span class="font1"> akibat prosedur &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.</span></p>
<p><span class="font1">selain yang telah disebutkan.[14,19] Prosedur terapi fotodinamik dapat diulang dan dilakukan sesuai kebutuhan tanpa kerusakan jaringan normal, toksisitas kumulatif, dan gangguan pada terapi konvensional. Tidak ditemukan interaksi obat dan intoleransi dengan terapi anti kanker lainnya.[18] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.</span></p>
<p><span class="font1">Secara garis besar, tidak ditemukan masalah fungsional maupun estetik yang persisten, adapun &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.</span></p>
<p><span class="font1">komplikasi yang ada dapat dikendalikan dan tidak bersifat fatal.</span></p>
<p><span class="font1">10. </span><span class="font1" style="font-weight:bold;">SIMPULAN</span></p>
<p><span class="font1">Terapi fotodinamik efektif dalam tatalaksana </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> stadium dini dilihat dari r</span><span class="font1" style="font-style:italic;">esponse rate</span><span class="font1"> dan </span><span class="font1" style="font-style:italic;">survival rate</span><span class="font1"> yang baik, dengan tingkat rekurensi pasien yang rendah. Mekanisme kerja yang melatarbelakangi yakni iluminasi PS dengan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.</span></p>
<p><span class="font1">kehadiran oksigen mengakibatkan produksi ROS yang berujung destruksi sel kanker. Profil keamanan terapi baik dengan efek samping minimal dan dapat dikendalikan. Diharapkan studi ini dapat menjadi panduan dalam pertimbangan penerapan metode terapi fotodinamik sebagai opsi alternatif dalam &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.</span></p>
<p><span class="font1">tatalaksana </span><span class="font1" style="font-style:italic;">oral cancer</span><span class="font1"> stadium dini.</span></p>
<p><span class="font1">Keterbatasan dari tinjauan pustaka ini adalah jumlah sampel yang relatif kecil pada beberapa studi karena keterbatasan sumber daya, etik, dan bukti &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.</span></p>
<p><span class="font1">dasar </span><span class="font1" style="font-style:italic;">evidence-based medicine</span><span class="font1"> yang kurang adekuat untuk dilakukan dalam sampel besar dan desain RCT sehingga sebagian besar studi menggunakan desain retrospektif, selain itu metode pelaporan </span><span class="font1" style="font-style:italic;">survival rate</span><span class="font1">, jumlah intervensi dan evaluasi yang bervariasi yang berpotensi menimbulkan bias antara studi yang dibandingkan. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.</span></p>
<p><span class="font1" style="font-weight:bold;">SARAN</span></p>
<p><span class="font1">Diperlukan studi prospektif dan RCT dengan protokol intervensi spesifik serta sistematis untuk membuktikan efikasi dan mengoptimisasi regimen terapi fotodinamik lebih lanjut. Selain itu kami juga menyarankan agar dilakukan pengukuran dengan indikator QOL sebelum, saat dan sesudah intervensi &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.</span></p>
<p><span class="font1">untuk memprediksi respon pasien terhadap terapi yang diberikan.</span></p>
<p><span class="font1" style="font-weight:bold;">DAFTAR PUSTAKA</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">1. &nbsp;&nbsp;&nbsp;Rivera C. Essentials of oral cancer. International journal of clinical and experimental pathology 2015;8(9):11884- 94. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.</span></p></li>
<li>
<p><span class="font1">2. &nbsp;&nbsp;&nbsp;Minić I, Pejčić A. Oral Cancer: Incidence and Management. J Oral Cancer Res. 2018;2(1):23.</span></p></li>
<li>
<p><span class="font1">3. &nbsp;&nbsp;&nbsp;International Agency for Research on Cancer.</span></p></li></ul>
<p><span class="font1">Indonesia-Global &nbsp;&nbsp;&nbsp;&nbsp;Cancer &nbsp;&nbsp;&nbsp;Observatory.</span></p>
<p><span class="font1">Globocan 2020. 2021; 858:1-2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">4. &nbsp;&nbsp;&nbsp;Speight PM, Farthing PM. The pathology of oral cancer. British dental journal. 2018 Nov;225(9):841.</span></p></li>
<li>
<p><span class="font1">5. &nbsp;&nbsp;&nbsp;Golusiński W, Kubiak A, Trojanowski M, Korytowska A, Pietrysiak A, Manasterski J, Pychyński T, Golusiński P, Majchrzak E, Sówka</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">M, Szewczyk M. National Programme for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.</span></p></li></ul>
<p><span class="font1">Prevention and Early Detection of Head and Neck Cancer. Otolaryngologia polska= The</span></p>
<p><span class="font1">Polish otolaryngology. 2015 Jan 1;69(4):7-12.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">6. &nbsp;&nbsp;&nbsp;Kumar M, Nanavati R, Modi TG, Dobariya C.</span></p></li></ul>
<p><span class="font1">Oral cancer: Etiology and risk factors: A review.</span></p>
<div>
<p><span class="font1">Journal of cancer research and therapeutics. 2016 Apr 1;12(2):458-63</span></p>
<p><span class="font1">Ikeda H, Ohba S, Egashira K, Asahina I. The effect of photodynamic therapy with talaporfin sodium, a second-generation photosensitizer, on oral squamous cell carcinoma: A series of eight cases. Photodiagnosis and photodynamic therapy. 2018 Mar 1;21: 176-80</span></p>
<p><span class="font1">Wong TS, Wiesenfeld D. Oral cancer. Australian dental journal. 2018 Mar; 63: S91-9.</span></p>
<p><span class="font1">Shanti RM, O'Malley Jr BW. Surgical Management of Oral Cancer. Dental Clinics of North America. 2017 Oct 16;62(1):77-86.</span></p>
<p><span class="font1">Ikeda H, Tobita T, Ohba S, Uehara M, Asahina I. Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia. Photodiagnosis and photodynamic therapy. 2013 Sep 1;10(3):229-35.</span></p>
<p><span class="font1">Liu YQ, Wang XL, He DH, Cheng YX. Protection against chemotherapy-and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine. 2020 Oct 31:153402</span></p>
<p><span class="font1">Jerjes W, Upile T, Hamdoon Z, Mosse CA, Akram S, Hopper C. Photodynamic therapy outcome for oral dysplasia. Lasers in surgery and medicine. 2011 Mar;43(3):192-9.</span></p>
<p><span class="font1">Karakullukcu B, van Oudenaarde K, Copper MP, Klop WM, van Veen R, Wildeman M, Tan IB. Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients. European Archives of Oto-Rhino-Laryngology. 2011 Feb;268(2):281-8.</span></p>
<p><span class="font1">Karakullukcu B, Nyst HJ, van Veen RL, Hoebers FJ, Hamming–Vrieze O, Witjes MJ, de Visscher SA, Burlage FR, Levendag PC, Sterenborg HJ, Tan IB. mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: Development of a new method. Head &amp;&nbsp;neck. 2012 Nov;34(11):1597-606.</span></p>
<p><span class="font1">de Visscher SA, Melchers LJ, Dijkstra PU, Karakullukcu B, Tan IB, Hopper C, Roodenburg JL, Witjes MJ. mTHPC-mediated photodynamic therapy of early stage oral squamous cell carcinoma: a comparison to surgical treatment. Annals of surgical oncology. 2013 Sep;20(9):3076-82.</span></p>
<p><span class="font1">Jerjes W, Upile T, Hamdoon Z, Alexander Mosse C, Morcos M, Hopper C. Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma. Lasers in surgery and medicine. 2011 Aug;43(6):463-9.</span></p>
<p><span class="font1">Karakullukcu B, Stoker SD, Wildeman AP, Copper MP, Wildeman MA, Tan IB. A matched cohort comparison of mTHPC-mediated photodynamic therapy and trans-oral surgery of early stage oral cavity squamous cell cancer. European Archives of Oto-Rhino-Laryngology. 2013 Mar;270(3):1093-7.</span></p>
<p><span class="font1">Durbec M, Cosmidis A, Fuchsmann C, Ramade A, Céruse P. Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx. European Archives</span></p>
</div><br clear="all">
<p><span class="font1">of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oto-Rhino-Laryngology. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013</span></p>
<p><span class="font1">Mar;270(4):1433-9.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">19. &nbsp;&nbsp;&nbsp;Toratani S, Tani R, Kanda T, Koizumi K, Yoshioka Y, Okamoto T. Photodynamic therapy using Photofrin and excimer dye laser treatment for superficial oral squamous cell carcinomas with long-term follow up. Photodiagnosis and photodynamic therapy. 2016 Jun 1;14: 104-10.</span></p></li>
<li>
<p><span class="font1">20. &nbsp;&nbsp;&nbsp;Rigual N, Shafirstein G, Cooper MT, Baumann H, Bellnier DA, Sunar U, Tracy EC, Rohrbach DJ, Wilding G, Tan W, Sullivan M. Photodynamic therapy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3-(1′-hexyloxyethyl)</span></p></li></ul>
<p><span class="font1">pyropheophorbide a for cancer of the oral cavity. Clinical Cancer Research. 2013 Dec 1;19(23):6605-13.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">21. &nbsp;&nbsp;&nbsp;Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M. Photodynamic therapy of cancer: an update. CA: a cancer journal for clinicians. 2011 Jul;61(4):250-81.</span></p></li>
<li>
<p><span class="font1">22. &nbsp;&nbsp;&nbsp;Lin J, Ni G, Ding T, Lei S, Zhong L, Liu N, Pan K, Chen T, Zeng X, Xu H, Li T. Photodynamic Therapy for Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Photoenergy. 2021 Feb 16;2021.</span></p></li>
<li>
<p><span class="font1">23. &nbsp;&nbsp;&nbsp;Sai DL, Lee J, Nguyen DL, Kim YP. Tailoring photosensitive ROS for advanced photodynamic therapy. Experimental &amp;&nbsp;Molecular Medicine. 2021 Apr;53(4):495-504.</span></p></li>
<li>
<p><span class="font1">24. &nbsp;&nbsp;&nbsp;dos Santos AF, de Almeida DR, Terra LF, Baptista MS, Labriola L. Photodynamic therapy</span></p></li></ul>
<p><span class="font1">in cancer treatment-an update review. Journal of cancer metastasis and treatment. 2019 Mar 29;5.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">25. &nbsp;&nbsp;&nbsp;Benov L. Photodynamic therapy: current status and future directions. Medical Principles and Practice. 2015;24(Suppl. 1):14-28.</span></p></li>
<li>
<p><span class="font1">26. &nbsp;&nbsp;&nbsp;Hamblin MR. Upconversion in photodynamic therapy: &nbsp;&nbsp;plumbing the depths. Dalton</span></p></li></ul>
<p><span class="font1">Transactions. 2018;47(26):8571-80</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">27. &nbsp;&nbsp;&nbsp;Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers. 2011 Jun;3(2):2516-39.</span></p></li>
<li>
<p><span class="font1">28. &nbsp;&nbsp;&nbsp;Miki,Y.,Akimoto,J.,Moritake,K.,Hironaka,C.&amp;Fuji wara,Y.Photodynamictherapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells.Lasers Med. Sci.30,1739–1745 (2015)</span></p></li>
<li>
<p><span class="font1">29. &nbsp;&nbsp;&nbsp;Hou YJ, Yang XX, Liu RQ, Zhao D, Guo CX, Zhu AC, Wen MN, Liu Z, Qu GF, Meng HX. Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles. International Journal of Nanomedicine. 2020;15:6827.</span></p></li></ul>
<h2><a name="bookmark23"></a><span class="font1" style="font-weight:bold;"><a name="bookmark24"></a>LAMPIRAN</span></h2>
<p><span class="font1">Lampiran 1. Tabel Karakteristik Studi</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Penulis</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Toratani et al.<sup>[19]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">de Visscher et al.<sup>[15]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Ikeda et al.<sup>[10]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Ikeda et al.<sup>[7]</sup></span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Tahun</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">2016</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">2013</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">2013</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">2018</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Setting</span><span class="font1" style="font-weight:bold;">/Tem pat</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Jepang</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Belanda</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Jepang</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Jepang</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Sampel (kriteria)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Secara histopatologis terdiagnosis OSCC</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Lesi ≤ 5 mm berdasarkan palpasi klinis dan CT scan</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Bukan lesi metastasis</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">• Terdiagnosis</span></p>
<p><span class="font1">OSCC dengan infiltrasi lesi ≤ 5 mm berdasarkan tomografi, MRI, ataupun ultrasound</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Terbukti OSCC tingkat </span><span class="font1" style="font-style:italic;">moderate </span><span class="font1">hingga </span><span class="font1" style="font-style:italic;">severe oral mucosal dysplasia</span><span class="font1"> secara biopsi di kavitas oris.</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Diameter tumor kurang dari 4 cm tanpa nodus limfe atau </span><span class="font1" style="font-style:italic;">distant metastasis</span><span class="font1">.</span></p></li></ul>
<p><span class="font1">• Kedalaman tumor kurang dari 5 mm</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Lesi yang didiagnosis</span></p></li></ul>
<p><span class="font1">OSCC</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Kedalaman tumor kurang dari 10mm • Tidak ada nodus limfe dan </span><span class="font1" style="font-style:italic;">distant metastasis</span></p></li></ul></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jumlah</span></p>
<p><span class="font1" style="font-weight:bold;">Sampel</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">34</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Intervensi: 152</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Kontrol: 91</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">25</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">8</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Gender </span><span class="font1" style="font-weight:bold;">(</span><span class="font1" style="font-weight:bold;font-style:italic;">Male</span><span class="font1" style="font-weight:bold;">%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">35.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Intervensi: 55</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Kontrol: 57</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">92.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">33.3</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Rata-rata umur</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">70.8</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Intervensi: 61.1</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Kontrol: 61.2</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">74.5</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">70.8</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jenis </span><span class="font1" style="font-weight:bold;font-style:italic;">Laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Excimer dye laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jenis PS</span></p></td><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1">Photofrin (porfimer sodium)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">mTHPC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Photofrin (porfimer sodium)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Talapor fin</span></p>
<p><span class="font1">Sodium</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Wavelengt</span><span class="font1" style="font-weight:bold;">h (nm)</span></p></td><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1">630</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">630</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">630</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">664</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Radiant Exposure</span></p>
<p><span class="font1" style="font-weight:bold;">(J/cm2)</span></p></td><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1">100–150</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">100</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">100</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">100</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Kontrol</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Transoral surgical resection</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">I</span></p>
<p><span class="font1" style="font-weight:bold;">Lokasi Lesi</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Upper Alveolar</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Lower Alveolar</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">•</span><span class="font1"> &nbsp;&nbsp;&nbsp;Linguae</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Buccal Mucosa</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">•</span><span class="font1"> &nbsp;&nbsp;&nbsp;Cavitas Oris Propria</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">N/A</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Linguae</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Gingiva</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Buccal Mucosa</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">•</span><span class="font1"> &nbsp;&nbsp;&nbsp;Cavitas Oris Propria</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Linguae</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">•</span><span class="font1"> &nbsp;&nbsp;&nbsp;Gingiva</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Lower Lip</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Buccal</span></p></li></ul>
<p><span class="font1" style="font-style:italic;">Mucosa</span></p></td></tr>
</table>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1">Median: 105 bulan</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Follow-Up</span></p>
<p><span class="font1" style="font-style:italic;">Range</span><span class="font1">: 68-156 bulan</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Median</span></p>
<p><span class="font1">Total: 48</span></p>
<p><span class="font1">Intervensi: 33 bulan &nbsp;&nbsp;&nbsp;Total: 24 bulan</span></p>
<p><span class="font1">bulan</span></p>
<p><span class="font1">Kontrol: 67 bulan</span></p></td></tr>
</table>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Penulis</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Jerjes et al.<sup>[12]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Jerjes et al.<sup>[16]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Karakullukcu et al.<sup>[13]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Karakullukc u et al.<sup>[14]</sup></span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Tahun</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2011</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2011</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2011</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">2012</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Setting</span><span class="font1" style="font-weight:bold;">/Te mpat</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Inggris</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Inggris</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Belanda</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Belanda</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">• SCC</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font1">• Lesi yang</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">berulang</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">didiagnosis OSCC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">nonmetastat</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Sampel</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">• Lesi yang</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">• Lesi yang</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">menurut biopsi</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">ik pada</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">(kriteria)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">didiagnosis OSCC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">didiagnosis OSCC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">• Kedalaman tumor</span></p></td><td style="vertical-align:top;">
<p><span class="font1">dasar lidah</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">kurang dari sama</span></p></td><td style="vertical-align:top;">
<p><span class="font1">setelah</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font1">dengan 5 mm</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">(kemo)radiot</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">erapi</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jumlah</span></p>
<p><span class="font1" style="font-weight:bold;">Sampel</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">147</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">38</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">170</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">20</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Gender </span><span class="font1" style="font-weight:bold;">(</span><span class="font1" style="font-weight:bold;font-style:italic;">Male</span><span class="font1" style="font-weight:bold;">%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">55.7</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">68.4</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">52.9</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">65</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Rata-rata</span></p>
<p><span class="font1" style="font-weight:bold;">umur</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">53</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">58</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">60.5</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">64</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jenis </span><span class="font1" style="font-weight:bold;font-style:italic;">Laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jenis PS</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">5- ALA &nbsp;mTHPC</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">mTHPC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">mTHPC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">mTHPC</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Wavelengt</span><span class="font1" style="font-weight:bold;">h (nm)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">628 &nbsp;&nbsp;&nbsp;&nbsp;652</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">652</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">652</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">652</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Radiant</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Exposure</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">100-200</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">10-20</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">20</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">30</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">(J/cm2)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Kontrol</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">• Linguae</span></p>
<p><span class="font1">• Palatum</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">Molle</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Lokasi Lesi</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">• Linguae</span></p>
<p><span class="font1">• Gingiva</span></p>
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">Lower Lip</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">• Linguae</span></p>
<p><span class="font1">• Cavitas Oris Propria</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">• Linguae</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Cavitas oris propria</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum Molle</span></p></li></ul></td><td style="vertical-align:bottom;">
<p><span class="font1">• Tonsil Linguae</span></p>
<p><span class="font1">• Oropharynx</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1" style="font-style:italic;">• Buccal Mucosa</span></p></td><td style="vertical-align:top;">
<p><span class="font1">• </span><span class="font1" style="font-style:italic;">Buccal Mucosa</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">• Prosesus Alveolaris</span></p></td><td style="vertical-align:top;">
<p><span class="font1">• Larynx</span></p>
<p><span class="font1">•</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">Hypopharyn</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font1">x</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">• Epiglottis</span></p></td></tr>
</table>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;font-style:italic;">Follow-Up</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Mean: 7.3 tahun &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Min:</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">5 tahun &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total: 60 bulan</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 minggu sekali selama 2 bulan, dan sekali tiap bulannya hingga waktu kematiannya</span></p>
<p><span class="font1">.</span></p></td></tr>
<tr><td colspan="4" style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Penulis</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Karakullukcu et al.<sup>[17]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Durbec et al.<sup>[18]</sup></span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Rigual et al.<sup>[20]</sup></span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Tahun</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2013</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">2013</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">2013</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Setting</span><span class="font1" style="font-weight:bold;">/Temp at</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Belanda</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Perancis</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">Amerika</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Sampel (kriteria)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">• OSCC</span></p>
<p><span class="font1">• Tumor dengan ketebalan kurang dari 5 mm dan tanpa terdeteksi metastasis nodus leher</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Rekurensi </span><span class="font1" style="font-style:italic;">oral cavity</span><span class="font1">/ oropharynx carcinoma atau kemunculan tumor yang kedua kalinya</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Memiliki tumor tunggal</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;tidak ada metastasis di nodus limfe / organ lain</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Displasia sedang atau berat</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Lesi yang didiagnosis OSCC menurut biopsi</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;carsinoma in situ / T1 OSCC</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Ketebalan tumor 4mm atau kurang</span></p></li></ul></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jumlah</span></p>
<p><span class="font1" style="font-weight:bold;">Sampel</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">98</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">15</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">41</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Gender </span><span class="font1" style="font-weight:bold;">(</span><span class="font1" style="font-weight:bold;font-style:italic;">Male</span><span class="font1" style="font-weight:bold;">%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">60</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">66.67</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">68.29</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Rata-rata</span></p>
<p><span class="font1" style="font-weight:bold;">umur</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">60</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">66.67</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">65</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Jenis Laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Diode laser</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-style:italic;">Non-thermal laser </span><span class="font1">dengan pancaran sinar dari </span><span class="font1" style="font-style:italic;">diode</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-style:italic;">Dye laser</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Jenis PS</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">mTHPC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">mTHPC</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">HPPH</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;">Wavelength (nm)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">652</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">652</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">665</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Radiant Exposure </span><span class="font1" style="font-weight:bold;">(J/cm2)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">N/A</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">20</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">75-140</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Kontrol</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">PDT bisa mencapai kontrol lokal OSCC stadium awal pada tingkat yang sebanding dengan reseksi trans-oral</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">N/A</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1">N/A</span></p></td></tr>
</table>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Lokasi Lesi</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Linguae</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Labium</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Buccal Mucosa</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Processus Alveolaris</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum Durum</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Trigonum Retromolar</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Cavitas Oris Propria</span></p></li></ul></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Linguae</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum molle</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Trigonum Retromolar</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Cavitas Oris Propria</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Vallecula</span></p></li>
<li>
<p><span class="font1">•</span><span class="font1" style="font-style:italic;"> &nbsp;&nbsp;&nbsp;Gingival Crest</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Posterior pharyngeal wall</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Lateral Rhinopharyngeal wall</span></p></li></ul></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum Molle</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Palatum Durum</span></p></li>
<li>
<p><span class="font1" style="font-style:italic;">• &nbsp;&nbsp;&nbsp;Buccal Mucosa</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Linguae</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Gingiva</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Cavitas Oris Propria</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Trigonum Retromolar • </span><span class="font1" style="font-style:italic;">Buccal Commisure</span></p></li></ul></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">I</span></p>
<p><span class="font1" style="font-weight:bold;font-style:italic;">Follow-Up</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Minimal 2 tahun</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Setiap minggu sekali pada</span></p>
<p><span class="font1">1 bulan pertama, dilanjutkan dengan sekali dalam 2 bulan untuk</span></p>
<p><span class="font1">1 tahun pertama, sekali dalam 3 bulan untuk tahun kedua dan ketiga, sekali dalam 4 bulan untuk tahun keempat dan kelima, dan setiap 2 tahun hingga kematian.</span></p></td><td style="vertical-align:top;">
<p><span class="font1">I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I</span></p>
<p><span class="font1">Interval 3-6 bulan</span></p></td></tr>
</table>
<p><span class="font1">HPPH, 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-alpha. mTHPC, meta-tetrakis (3-hydroxyphenyl) chlorin.</span></p>
<p><span class="font1">OSCC, </span><span class="font1" style="font-style:italic;">Oral Squamous Cell Carcinoma.</span><span class="font1"> PDT, </span><span class="font1" style="font-style:italic;">Photodynamic Therapy.</span><span class="font1"> PS, </span><span class="font1" style="font-style:italic;">Photosensitizer</span><span class="font1">. SCC, </span><span class="font1" style="font-style:italic;">Squamous Cell Carcinoma</span><span class="font1">. 5-ALA, 5-aminolevulinic </span><span class="font1" style="font-style:italic;">acid</span></p>
<p><span class="font3" style="font-weight:bold;">54</span></p>
<p><a href="https://ojs.unud.ac.id/index.php/essential/index"><span class="font2">https://ojs.unud.ac.id/index.php/essential/index</span></a></p>